Mertanzin

Mertanzin
Nazivi
	Drugi nazivi Maytansinoid DM1; N2'-deacetil-N2'-(3-merkapto-1-oksopropil)-majtanzin
Identifikacija
3D model (Jmol)	interaktivna slika;
ECHA InfoCard	100.168.831
PubChem C ID	11343137;
	SMILES CC1C2CC(C(C=CC=C(CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)CC(C4(C1O4)C)OC(=O)C(C)N(C)C(=O)CCS)C)C)OC)(NC(=O)O2)O; ; ; ; ; ;
Svojstva
Hemijska formula	C35H48ClN3O10S
Molarna masa	738,29 g·mol−1
	Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa).
	verifikuj (šta je ?)
	Reference infokutije

Mertanzin je citotoksični agens, takođe poznat kao DM1. On je majtanzinoid (derivat majtanzina).^[3]

Upotreba

Sledeći lekov su konjugati antela i leka koji kombinuju monoklonalna antitela sa mertanzinom kao citotoksičnom komponentom. Mertanzin je vezan putem 4-merkaptovalerinske kiseline.

Bivatuzumab mertanzin
Cantuzumab mertanzin
Lorvotuzumab mertanzin (IMGN901) za CD56 pozitivne kancere, na primer multiplu mijelomu^[4]

Mertanzin takođe može da bude vezan putem komplikovanije strukture – 4-(3-merkapto-2,5-diokso-1-pirolidinilmetil)-ciloheksanekarboksilne kiselne ili MCC –, u kom slučaju se ime konjugata formira sa emtanzin:

Trastuzumab emtanzin (T-DM1), anti-HER2/neu konjugat antitela i leka^[5]^[6]

Reference

^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди
^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
^ Tijink, BM; Buter, J; De Bree, R; Giaccone, G; Lang, MS; Staab, A; Leemans, CR; Van Dongen, GA (2006). „A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus”. Clinical cancer research : an official journal of the American Association for Cancer Research. 12 (20 Pt 1): 6064—72. PMID 17062682. doi:10.1158/1078-0432.CCR-06-0910.
^ „ImmunoGen reports encouraging clinical data of IMGN901”. The Medical News. 6. 12. 2009.
^ National Cancer Institute: trastuzumab-MCC-DM1 antibody-drug conjugate
^ Immunogen: Trastuzumab-DM1 Архивирано на сајту Wayback Machine (20. октобар 2010)

Spoljašnje veze

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди

[2] Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.

[3] Tijink, BM; Buter, J; De Bree, R; Giaccone, G; Lang, MS; Staab, A; Leemans, CR; Van Dongen, GA (2006). „A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus”. Clinical cancer research : an official journal of the American Association for Cancer Research. 12 (20 Pt 1): 6064—72. PMID 17062682. doi:10.1158/1078-0432.CCR-06-0910.

[4] „ImmunoGen reports encouraging clinical data of IMGN901”. The Medical News. 6. 12. 2009.

[5] National Cancer Institute: trastuzumab-MCC-DM1 antibody-drug conjugate

[6] Immunogen: Trastuzumab-DM1 Архивирано на сајту Wayback Machine (20. октобар 2010)

[1]

[2]

[3]

[4]

[5]

[6]